Moderna Stock Current Asset
| MRNA Stock | USD 38.25 1.31 3.55% |
Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock.
Moderna |
Moderna Company Current Asset Analysis
Moderna's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Moderna Current Asset | 850 K |
Most of Moderna's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Moderna has a Current Asset of 850 K. This is 99.96% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The current asset for all United States stocks is 99.99% higher than that of the company.
Moderna Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moderna's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moderna could also be used in its relative valuation, which is a method of valuing Moderna by comparing valuation metrics of similar companies.Moderna is currently under evaluation in current asset category among its peers.
Moderna Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 8.84 B | ||||
| Shares Outstanding | 384.82 M | ||||
| Shares Owned By Insiders | 9.52 % | ||||
| Shares Owned By Institutions | 71.56 % | ||||
| Number Of Shares Shorted | 34.38 M | ||||
| Price To Earning | 6.37 X | ||||
| Price To Book | 1.20 X | ||||
| Price To Sales | 2.80 X | ||||
| Revenue | 6.85 B | ||||
| Gross Profit | 10.55 B | ||||
| EBITDA | (3.28 B) | ||||
| Net Income | (4.71 B) | ||||
| Cash And Equivalents | 8.35 B | ||||
| Cash Per Share | 21.73 X | ||||
| Total Debt | 1.24 B | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 2.10 X | ||||
| Book Value Per Share | 30.98 X | ||||
| Cash Flow From Operations | (3.12 B) | ||||
| Short Ratio | 7.59 X | ||||
| Earnings Per Share | (5.81) X | ||||
| Target Price | 77.55 | ||||
| Number Of Employees | 5.6 K | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 14.22 B | ||||
| Total Asset | 18.43 B | ||||
| Retained Earnings | 13.61 B | ||||
| Working Capital | 7.31 B | ||||
| Current Asset | 850 K | ||||
| Current Liabilities | 2.44 M | ||||
| Net Asset | 18.43 B |
About Moderna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Moderna Piotroski F Score and Moderna Altman Z Score analysis. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.